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Purpose
Systemic lupus erythematosus (SLE) is a chronic multi-
system autoimmune disease affecting various organs,
with lupus nephritis being one of the most important
and common serious manifestations. Antimalarials (AM)
are one of the many immunomodifying medications
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Figure 1 Overview of effects of antimalarials on lupus disease and activity – articles from 2005 to 2010. LN=lupus nephritis.
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Figure 2 Overview of effects of antimalarials on cardiovascular disease and thrombosis – articles from 2005-2010. CVD = cardiovascular disease.
aPL = antiphospholipid antibodies. TE = thromboembolic events. RA = rheumatoid arthritis.
Figure 3 Overview of studies on AMs and outcomes related to LN. MMF = mycophenolate mofetil.
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used in SLE, however less known is its role in lupus
nephritis. Our study examined the history of AM use,
theorized mechanisms of action, efficacy in SLE, in par-
ticular in lupus nephritis, safety in pregnancy, and over-
all safety profile.
Methods
We conducted a search of all relevant literature using
Medline (OVID and EMBASE) and PubMed. We
included randomized-controlled trials, observational
cohort studies, and case-control studies. Case reports
were only included for the adverse effect profile of
AM.
Results
•AM use benefits patients with SLE including improv-
ing survival, reducing disease activity, new organ invol-
vement, integument damage, risk of infection, risk of
Figure 4 Overview of AM potential toxicity/adverse events
Lee et al. Pediatric Rheumatology 2012, 10(Suppl 1):A29
http://www.ped-rheum.com/content/10/S1/A29
Page 3 of 4
thrombosis, and possible cardioprotective and anti-
malignancy effects.
•In lupus nephritis, AM use improves time to end-
stage renal disease, disease activity, flare rates, disease
remission as an adjunct with other immunomodifying
drugs, and reduced cumulative corticosteroid use.
•AM are safe to use and should be continued in pregnant
SLE patients for its beneficial effects of reducing disease
activity, flare rates, cumulative corticosteroid requirements,
and possible reduction in development of cardiac neonatal
lupus erythematosus.•AM have a good safety profile, with
gastrointestinal symptoms being the most common. Care-
ful regular monitoring for retinopathy is recommended as
per American Academy of Ophthalmology.
•In patients with renal disease, caution with dosing and
careful monitoring for adverse events should be taken.
Conclusion
AM are medications which confer many benefits to
patients with SLE and lupus nephritis, with a good
safety profile.
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